Research
Viloxazine has undergone two randomized controlled trials for nocturnal enuresis (bedwetting) in children, both of those times versus imipramine. By 1990, it was seen as a less cardiotoxic alternative to imipramine, and to be especially effective in heavy sleepers.In narcolepsy, viloxazine has been shown to suppress auxiliary symptoms such as cataplexy and also abnormal sleep-onset REM without really improving daytime somnolence. In a cross-over trial (56 participants) viloxazine significantly reduced EDS and cataplexy.Viloxazine has also been studied for the treatment of alcoholism, with some success.While viloxazine may have been effective in clinical depression, it did relatively poorly in a double-blind randomized controlled trial versus amisulpride in the treatment of dysthymia. References
External links
"Viloxazine". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT03247530 for "Evaluation of SPN-812 ER Low Dose in Children With ADHD" at ClinicalTrials.gov
Clinical trial number NCT03247543 for "Evaluation of SPN-812 ER High Dose in Children With ADHD" at ClinicalTrials.gov
The first virus isolates were obtained during this outbreak from mosquitoes and human blood samples collected from Gulu in northern Uganda in 1959.The second epidemic in 1996–1997 was confined to Uganda. The 35-year hiatus between the two outbreaks and evidence of an outbreak in 1904–1906 in Uganda indicate a 30–50 year cycle for epidemics.In 2013, ONNV was confirmed as the cause of disease in a 60-year-old German woman who became infected while traveling in East Africa. In 2015–2016 there was a minor outbreak in Uganda with 51 suspected cases.There has been a minor outbreak in Mombasa (Kenya) and the County Government of Mombasa issued a warning. A 2015 study indicated that ONNV is endemic in coastal East Africa, along with chikungunya virus. References


== External links ==